Final Programme - iuphar

More documents

Recommendations

Info

FC10 Drugs for half the world: Paediatric clinical pharmacology Wed 017 Pharmacokinetics and outcomes of gentamicin therapy in neonates critically ill during the first week of life: Volumes of fluid infused or retained as possible covariates Jirina Martinkova, (Czech Republic), P Pokorná, J Záhora, J Chladek, V Vobruba, I Selke-Krulichova, J Chladkova Wed 018 Does budesonide applied in prevention of child asthma affect variations in body weight in asthmatic children? Milica Martinovic, (Republic of Serbia) Wed 019 Does budesonide applied in prevention of child asthma decrease height velocity of asthmatic children? Milica Martinovic, (Republic of Serbia), S Pantovic 246 Wednesday 21 July ■ 13:00 - 14:00 ■ Poster Area
FC11 G protein-coupled 7TM receptors: From molecular to physiological function Wed 020 Development of a P2X7 binding and Ex vivooccupancy assay in rat brain Sarah Able, (UK), R Fish, L Booth, S Katugampola Wed 021 Cerebrovascular contractile receptors up-regulate via a Raf sensitive signalling pathway Hilda Ahnstedt, (Sweden), L Edvinsson Wed 022 Pre-versus postsynaptic α2A-adrenoceptors functions mediated via Gαi-isoforms Julian Albarran-Juarez, (Germany), R Gilsbach, R Piekorz, K Pexa, B Nürnberg, L Hein Wed 023 Palmitoyl CoA antagonism of ADP-induced relaxation of rat thoracic aorta Eman Alefishat, (UK), S Alexander, V Ralevic Wed 024 Muscarinic m3AchR is regulated by cGMP, via a PKG-II dependent phosphorylation in plasma membranes from tracheal smooth muscle Marcelo J Alfonzo, (Venezuela), M Alfonzo-Gonzalez, RG Alfonzo, A Misle, IL Becemberg Wed 025 Role of receptor recycling in the recovery of Ca 2+ signalling by recombinantly expressed neuromedin U 2 receptors (NMU2) Khaled Al-Hosaini, (UK), RAJ Challiss, GB Willars Wed 026 FRET-based evidence for ligand-independent preassociation of 5-HT7 serotonin receptors with Gs Kjetil W Andressen, (Norway), L Hommers, AH Ulsund, MJ Lohse, KA Krobert, M Bünemann, FO Levy Wed 027 Antimitogenic and apoptotic effects of selective 5HT3 receptor antagonist on HT29 colorectal cancer cell line. Ramin Ataee, (Iran), M Zarrindast, S Ajdary, S Sharyari Wed 028 REEP family members modulate α2C-adrenoceptor expression by an ER interaction Susann Björk, (Finland), C Hurt, B Kobilka, T Angelotti Wed 029 CRIP1a regulates CB1 cannabinoid receptor internalization and signal transduction Lawrence C Blume, (USA), CC Bass, GD Dalton, DE Selley, A Howlett Wed 030 Protein kinase C (PKC) regulation of type 5 metabotropic glutamate (mGlu5) receptor-stimulated Ca2+ oscillations in rat cerebrocortical astroglia Sophie J Bradley, (UK), JM Watson, RAJ Challiss Wed 031 The inverse agonist effect of rimonabant in brain membranes is not mediated by the CB1 receptor Luis F Callado, (Spain), AM Erdozain, R Diez-Alarcia, JJ Meana Wed 032 Modulation of ligand binding to the α1B adrenergic receptor: a potential role for the second extracellular loop Adrian Campbell, (Australia), I McDougal, R Griffith, A Finch Wed 033 Long-term cigarette smoke exposure induces bronchial hyperresponsiveness to G-protein coupled receptor agonists Lei Cao, (Sweden), Y Zhang, Y-X Cao, L Edvinsson, C-B Xu Wed 034 mmLDL upregulates endothelin type A and type B receptors in rat basilar artery Yong-Xiao Cao, (PR China), J Li, ZY Yuan, L Cao, CB Xu Wed 035 Activation of OX1, but not OX2, receptors in the periaqueductal gray produces antinociception via retrograde endocannabinoid-induced disinhibition Lih-Chu Chiou, (Taiwan), Y-C Ho, H-J Lee, Y-Y Liao, S-Y Fu, S-F Teng, H-T Liao Wednesday 21 July ■ 13:00 - 14:00 ■ Poster Area 247
Page 1:
of basic and clinical pharmacology
Page 4 and 5:
Congress patron 2 HRH Crown Princes
Page 6 and 7:
Congress President Kim Brøsen Secr
Page 8 and 9:
General information Registration &
Page 10 and 11:
Banks, currency & credit cards The
Page 12 and 13:
Information to presenters ■ The a
Page 14 and 15:
Hotel Bella Center Copenhagen Groun
Page 16 and 17:
Programme at a glance Time Hall A2
Page 18 and 19:
16 General events General events Op
Page 20 and 21:
Programme outline Plenary lectures
Page 22 and 23:
FC10 Drugs for half the world: Paed
Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
Page 26 and 27:
W01 Pharmacology of adrenoceptors:
Page 28 and 29:
W02 Symposium on advances in GI pha
Page 30 and 31:
W04 Symposium: Antioxidants as ther
Page 32 and 33:
Plenary lectures PL01 Plenary lectu
Page 34 and 35:
FC02 Transmembrane transport: Persp
Page 36 and 37:
FC04 Pharmacoepidemiology, current
Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
Page 40 and 41:
FC09 Inflammation and immunopharmac
Page 42 and 43:
W02 Symposium on advances in GI pha
Page 44 and 45:
SS01 Sponsored symposium Sponsored
Page 46 and 47:
W06 Workshop. Effect of disease on
Page 48 and 49:
W08 Workshop. Identifying targets f
Page 50 and 51:
W10 Workshop. Innovative Medicines
Page 52 and 53:
FC01 Clinical pharmacology in the e
Page 54 and 55:
FC03 Ion channels in analgesia and
Page 56 and 57:
FC05 Translational science in the m
Page 58 and 59:
Page 60 and 61:
FC08 Development in the treatment o
Page 62 and 63:
Plenary lectures PL04 Plenary lectu
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
FC07 Simulation and data modelling
Page 72 and 73:
Page 74 and 75:
W12 Workshop. Experimental pain met
Page 76 and 77:
W14 Workshop. Translating the human
Page 78 and 79:
W15 Workshop. The IUPHAR initiative
Page 80 and 81:
W17 Workshop. Standards for PhD Edu
Page 82 and 83:
W19 Workshop. Influence of degenera
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
FC08 Development in the treatment o
Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
Page 94 and 95:
FC10 Drugs for half the world: Paed
Page 96 and 97:
FC12 Ion channelopathies: New windo
Page 98 and 99:
FC14 Addiction and doping: Neurobio
Page 100 and 101:
FC17 New approaches and targets in
Page 102 and 103:
W04 Symposium: Antioxidants as ther
Page 104 and 105:
W21 Workshop. Inflammation - here,
Page 106 and 107:
W23 Workshop. Applying pharmacogeno
Page 108 and 109:
W25 Workshop. High science in the l
Page 110 and 111:
W27 Workshop. Approaches to medicin
Page 112 and 113:
FC11 G protein-coupled 7TM receptor
Page 114 and 115:
FC13 Maximising benefits and minimi
Page 116 and 117:
FC15 Endothelium in Health and dise
Page 118 and 119:
Page 120 and 121:
FC18 Nuclear receptor targets for t
Page 122 and 123:
PL16 Plenary Lecture Supported by a
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
FC15 Endothelium in Health and dise
Page 130 and 131:
Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
Page 134 and 135:
W30 Workshop. Is eNOS still a valid
Page 136 and 137:
W32 Workshop. The good, the bad and
Page 138 and 139:
W34 Workshop. State-of-the-art of b
Page 140 and 141:
FC10 Drugs for half the world: Pedi
Page 142 and 143:
FC12 Ion channelopathies: New windo
Page 144 and 145:
FC14 Addiction and doping: Neurobio
Page 146 and 147:
FC16 Natural products: Past and fut
Page 148 and 149:
Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
FC15 Endothelium in health and dise
Page 158 and 159:
Page 160 and 161:
158
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
W12 Experimental pain methods in de
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
FC06 The heart gone wrong; stabiliz
Page 180 and 181:
FC07 Simulation and data modelling
Page 182 and 183:
FC08 Developments in the treatment
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
W03 Targeting TRP channels for pain
Page 196 and 197:
W19 Influence of degeneration and r
Page 198 and 199: W19 Influence of degeneration and r
Page 200 and 201: W20 Pharmacology education for a su
Page 202 and 203: FC01 Clinical pharmacology in the e
Page 204 and 205: FC02 Transmembrane transport: Persp
Page 206 and 207: FC02 Transmembrane transport: Persp
Page 208 and 209: FC04 Pharmacoepidemiology, current
Page 210 and 211: FC05 Translational science in the m
Page 212 and 213: FC05 Translational science in the m
Page 214 and 215: FC06 The heart gone wrong; stabiliz
Page 216 and 217: FC07 Simulation and data modelling
Page 218 and 219: FC08 Developments in the treatment
Page 220 and 221: FC09 Inflammation and immunopharmac
Page 226 and 227: FC13 Maximising benefits and minimi
Page 230 and 231: FC19 General session Tue 361 Analge
Page 232 and 233: FC19 General session - Biologics Tu
Page 234 and 235: FC19 General session - Haematology
Page 236 and 237: FC19 General session - oncology Tue
Page 238 and 239: FC19 General session - oncology Tue
Page 240 and 241: FC19 General session - Toxicology T
Page 242 and 243: W02 Symposium on advances in GI pha
Page 244 and 245: W11 New opportunities in the pharma
Page 246 and 247: W23 Applying pharmacogenomics (PGX)
Page 250 and 251: FC11 G protein-coupled 7TM receptor
Page 254 and 255: FC12 Ion channelopathies: New windo
Page 260 and 261: FC14 Addiction and doping: Neurobio
Page 262 and 263: FC15 Endothelium in health and dise
Page 268 and 269: W30 Is eNOS Still a valid therapeut
Page 270 and 271: FC16 Natural products: Past and fut
Page 276 and 277: FC17 New approaches and targets in
Page 278 and 279: FC17 New approaches and targets in
Page 280 and 281: W34 State-of-the-art of basic and c
Page 282 and 283: FC10 Drugs for half the world: Paed
Page 294 and 295: W29 New horizons in therapeutic dru
Page 296 and 297: FC14 Addiction and doping: Neurobio
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
314 Index Name Paper ref. Name Pape
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
Page 384 and 385:
382 Notes Notes
Page 386:
Final Programme printed in Singapor
show all

Final Programme - iuphar

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?